Please login to the form below

Not currently logged in
Email:
Password:

Astellas appoints Dr Songlin Xue head of global pharmacovigilance

He joins from Takeda and was formerly at Novartis and Wyeth

Dr Songlin Xue has moved to Astellas Pharma to take up the US-based role of head of global pharmacovigilance (PV).

He will work out of the Japanese pharma company's Northbrook, Illinois headquarters for the Americas and report to Astellas chief medical officer Sef Kurstjens.

Dr Xue has spent more than 20 years in the pharmaceutical industry, most recently at Takeda, where he was senior vice president, head global pharmacovigilance.

Prior to joining Takeda, Dr Xue held posts with a number of global pharmaceutical companies, including Novartis and Wyeth. 

Astellas president and CEO Yoshihiko Hatanaka said: “I am pleased that Dr Xue will be joining us at Astellas as head of global pharmacovigilance. Dr Xue's knowledge and experience will help the company pursue its operational excellence and further enhance our global PV and product compliance capabilities.”

16th April 2013

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics